全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Postponing AMI to 100 Years: An Emerging Concept

DOI: 10.4236/wjcd.2024.146034, PP. 401-408

Keywords: Acute Myocardial Infarction, Cumulative Exposure of LDL-C, Inclisiran, CRISPR Technology

Full-Text   Cite this paper   Add to My Lib

Abstract:

Acute myocardial infarction is a deadly disease, and in the Indian context, it occurs at a younger age, even below the age of 40 years, and sometimes even below 30 years. These young MI patients have high mortality rates, and many of them are not able to reach the hospital. The pathophysiology of AMI is very well understood. AMI is a multifactorial disease and has several risk factors, like dyslipidemia, diabetes, hypertension, smoking, diet, etc. However, low-density lipoprotein cholesterol (LDL-C) has a very strong causal relationship with atherosclerosis. Reducing LDL-C to <70 results in the arrest of the progression of atherosclerosis, and slashing its level to below 50 produces the regression of atherosclerosis. The cumulative exposure of LDL-C to the arterial wall is a very strong determinant of atherosclerosis and the development of AMI. The coronary heart disease (CHD) threshold target of LDL-C for the development of AMI is roughly 7000 mg/year. If LDL-C is 100 mg/dL from an early age, the CHD threshold target for the development of AMI will reach 70 years of age. However, if LDL-C target is <70 mg/dL from an early age, the patients will reach the CHD threshold of LDL-C at the age of 100 years. Based on the current science, this is an emerging concept to postpone AMI by several years, even up to 100 years. The goal of LDL-C <70 mg/dL can be achieved by available oral or injectable drugs. Gene editing with CRISPR technology is emerging as a very exciting modality for lowering LDL-C to a very low level for the rest of life.

References

[1]  Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., Brown, B.G., Ganz, P., Vogel, R.A., et al. (2004) Effect of Intensive Compared with Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA, 291, 1071-1081.
https://doi.org/10.1001/jama.291.9.1071
[2]  Nicholls, S.J., Puri, R., Anderson, T., Ballantyne, C.M., Cho, L., Kastelein, J.J.P., et al. (2016) Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. JAMA, 316, 2373-2384.
https://doi.org/10.1001/jama.2016.16951
[3]  Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., et al. (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 376, 1713-1722.
https://doi.org/10.1056/nejmoa1615664
[4]  Shapiro, M.D. and Bhatt, D.L. (2020) “Cholesterol-Years” for ASCVD Risk Prediction and Treatment. Journal of the American College of Cardiology, 76, 1517-1520.
https://doi.org/10.1016/j.jacc.2020.08.004
[5]  VERVE-101: CRISPR-Based Gene Editing Therapy Shows Promise in Reducing LDL-C and PCSK9 Levels in Patients with HeFH Presented Nov. 12 at AHA 2023.
[6]  Ray, K.K., Troquay, R.P.T., Visseren, F.L.J., Leiter, L.A., Scott Wright, R., Vikarunnessa, S., et al. (2023) Long-Term Efficacy and Safety of Inclisiran in Patients with High Cardiovascular Risk and Elevated LDL Cholesterol (ORION-3): Results from the 4-Year Open-Label Extension of the ORION-1 Trial. The Lancet Diabetes & Endocrinology, 11, 109-119.
https://doi.org/10.1016/s2213-8587(22)00353-9

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133